No Data
The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.
Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to
Shengnuo Medical-B (02257.HK): Zhonghui Anda has been appointed as the auditor.
On December 13, Gelonghui reported that Shengnuo Medicine-B (02257.HK) announced that the company received a resignation letter dated December 13, 2024, from Deloitte Touche Tohmatsu. Following the recommendation of the Audit Committee, Zhonghui Anda Certified Public Accountants Limited ("Zhonghui Anda") has been appointed as the company's auditor, effective from December 13, 2024, to fill the temporary vacancy left by Deloitte's resignation, to serve until the end of the company's next annual general meeting of shareholders.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Saintno Pharmaceutical-B has completed the issuance of 17.5277 million shares.
Shengnuo Pharmaceutical-B (02257) announced that on December 2, 2024, it will issue 17.5277 million shares after completing the subscription of new shares according to the general authorization based on the subscription agreement dated October 2, 2024.
Express News | Sirnaomics Ltd - Got Letter of Resignation From Shing Mo Han, Yvonne to Resign as Chairperson of Board
Press Release: Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
